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 CURRENTOPINION Chronic obstructive pulmonary disease patient
journey: hospitalizations as window of opportunity
for extra-pulmonary intervention
Mitja Lainscaka,b, Harry R. Goskerc, and Annemie M.W.J. Scholsc
Purpose of review
Hospitalizations due to exacerbation of chronic obstructive pulmonary disease (COPD) are a major burden
for patient and healthcare system. Extra-pulmonary needs and resulting interventions are poorly
investigated.
Recent findings
COPD induces nutritional issues, body composition changes and limits patient exercise capacity. The
COPD patient journey can be accelerated through exacerbations during which disease-related detrimental
factors such as systemic inflammation, hypoxia, inactivity, and glucocorticosteroid treatment converge and
intensify, which acutely and often irreversibly worsens patient condition. Specific needs during
exacerbations reach beyond the respiratory system, thus clinicians should comprehensively evaluate
patients and identify potent and feasible metabolic and anabolic intervention targets. General and specific
nutritional support appear feasible and with potential to cover for the changed bodily requirements during
exacerbation. Adjunctive physical exercise or neuromuscular electrical stimulation may prevent the muscle
loss.
Summary
Hospitalizations should be considered as a window of opportunity for detailed patient assessment and
implementation of tailored extra-pulmonary adjunctive strategies with long-term implications. Nutritional
assessment and support as well as physical exercise appear promising but should be investigated in
adequately designed and conducted trials.
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INTRODUCTION
Global burden of disease will change in decades to
follow and chronic obstructive pulmonary disease
(COPD) will be a major player around the globe [1].
In addition to disease-associated mortality, COPD
patients take a journey of frequent exacerbations
(Fig. 1) leading to disease deterioration when
systemic inflammation, hypoxia, inactivity, and
glucocorticosteroid treatment converge and inten-
sify, commonly causing hospitalizations [2
&
] that
are main drivers of COPD-related costs [3]. Deter-
minants of vulnerable patient phenotypes and path-
ophysiological mechanisms behind the clinical
presentation are not well studied and remain largely
unknown [4]. A number of defense mechanisms are
induced that are generally phylogenetically old and
serve primarily for a swift response to resolve the
acute situations, but few effective drugs and pro-
cedures are available [5,6] to counteract the
deleterious mechanisms that remain chronically
(over)activated. Once at this stage, patients enter
a disability spiral [7
&
] with devastating implications
for body composition, skeletal muscle function,
physical performance, quality of life, and mortality,
all being highly clinically relevant [8].
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Whilst for clinically stable patients evidence and
resulting guidelines from well conducted studies
exist [9
&
,10], the applications during acute exacer-
bations remain scarce. This review therefore aims
to briefly summarize the available knowledge
about pathophysiological processes and their con-
sequences for COPD patients during acute exacer-
bations. We also discuss the potential therapeutic
targets during hospitalizations and ongoing research
that could, in light of few respiratory treatments with
prognostic implications, delay or even reverse the
COPD continuum.
DEPARTURE: THE EXACERBATION-
RELATED HOSPITALIZATION AND ITS
CONSEQUENCES
Particularly during exacerbations, COPD-related
detrimental factors such as systemic inflammation,
hypoxia, inactivity, and glucocorticosteroid treat-
ment converge and intensify [11]. Skeletal muscle is
particularly prone to damage; atrophy, and a
decreased oxidative phenotype develop early and
soon reach irreversible stages [12
&
,13]. A number of
mechanisms are involved and most of them can
interfere simultaneously with metabolic function,
muscle mass, and performance [14]. It is important
to note the complexity and interrelation of
regulatory processes involved induced by various
triggers including inflammation, renin-angioten-





]. Finally, we need to be aware of other
organs and systems that are usually neglected, but
have a major role in maintaining a metabolic bal-
ance in the body. While initially being considered as
merely an energy depot, fat tissue, for instance, has
recently emerged at the crossroads of many patho-
physiological processes with major implications for
energy turnover and anabolic/catabolic processes
and an important source of persistent systemic
inflammation [17]. Implications for COPD patients
are numerous and reach beyond the recently
described obesity paradox phenomenon [18
&
]. In
this context, it is important to evaluate not only
whole body fat content (generally protective in
chronic disease), but also its distribution through-
out the body. In clinically stable COPD, abdominal
visceral fat contributes to systemic inflammation
independent of BMI and total fat mass [19
&
], with
potentially detrimental effects on skeletal muscle
oxidative phenotype [20]. Most recent insight
regarding molecular pathways indicates that during
acute pulmonary inflammation, TNF-a-induced
NF-kB activation is required for the transition to
systemic inflammation and muscle atrophy [21].
This animal model study furthermore elegantly
KEY POINTS
 Hospitalizations are window of opportunity for
comprehensive patient assessment to identify specific
needs and therapeutic targets.
 Malnutrition, risk of malnutrition, and specific
deficiencies are common in COPD and need to be
treated adequately.
 COPD exacerbations mimic hypoxic inactivity, thus
sufficient anabolic drive through adjunctive
interventions is necessary.
















FIGURE 1. Exacerbation related hospitalizations: a window of opportunity for intervention.
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demonstrated the importance of malnutrition to act
hand in hand with inflammation, causing body
wasting and finally an irreversible state of cachexia,
out of reach of any known remedies available to
date.
Acute exarcerbations and commonly adminis-
trated high-dose glucocorticosteroids induce insulin
resistance, and decreased insulin sensitivity associ-
ated with a decreased muscle oxidative phenotype
has also been shown in the clinically stable con-
dition [12
&
]. Some nutritional interventions could
have potential to reverse inflammatory mechanisms
that induce insulin resistance, but the field is not
explored yet in COPD [22]. Along with activated
renin-angiotensin-aldosterone system and evidence
for activated peroxisome proliferator-activated
receptors [23], angiotensin receptor blockers or
sartanes appear to be more attractive interventions
to improve the insulin resistance. Although studies
in patients with COPD are scarce, Andreas et al. [24]
demonstrated that irbesartan was well tolerated,
safe, and associated with some ancillary benefits
in terms of haematocrite and total lung capacity,
thus setting the stage for further trials. More data are
available for patients with heart failure; the analysis
of large-scale Candesartan in Heart Failure: Assess-
ment of Reduction in Mortality and morbidity
program (N¼6933) demonstrated that weight loss
and being lean, particularly when combined, were
important predictors for poor prognosis. The weight
loss under candesartan therapy, however, was signi-
ficantly less common when compared to placebo
[25]. Combining this with observed pleiotropic
effects through peroxisome proliferator-activated
receptor activation mediated reduction of insulin
resistance could deliver several benefits for the
patients [26]. Indeed, in a recent placebo-controlled
double-blind trial, 36 patients were treated with
irbesartan or matching placebo [27]. After 4 months
of treatment, insulin resistance decreased in the
irbesartan (by 26%) but not the placebo group (treat-
ment effect P¼0.0026). Translating the knowledge
from patients with heart failure gives us reasonable
ground to consider such treatment in COPD, as
suggested previously [28].
CHANGE OF DIRECTION: METABOLIC
NEEDS AND NUTRITIONAL SUPPORT
COPD patients have higher energy needs due to
increased resting metabolic rate and whole body
protein turnover, which can eventually lead to body
wasting and cachexia [29]. Nutritional support has





]. During an exacerbation, the
energy and nutrient-specific needs exceed those in
stable state [31]. The subjective perception for food
intake is modified (e.g. loss of appetite due to the
illness) and patients may not be willing to adjust
their nutritional pattern during exacerbation [32].
To investigate potential for nutritional support
during hospitalization for exacerbation of COPD,
a double-blind study randomized 56 nutritionally
depleted patients to 3125 ml (2.38 MJ/day) of
energy and protein-rich fluid vs. matching non-
caloric placebo [33]. This intervention was feasible
and increased daily energy (15%) and protein (38%)
intake. Considering that 14–22% of hospitalized
COPD patients are malnourished or underweight,
and a further 55% are at risk of malnutrition
[34,35
&
,36], the hospitalization should be con-
sidered as a window of opportunity to intervene,
this time in a physiological manner in terms of
feeding and nutritional support. We should learn
from space medicine [37] and from top-level ath-
letes [38,39] where many novel applications or
nutritional compounds were tested and proved effi-
cacious. In a stable disease, general nutritional sup-
port as part of COPD management is validated [40]
in wasted COPD patients and cost-effective due to
reduced hospitalizations, thus transfer to acute
setting with potential extension in stable phase
is warranted.
In addition to calories and proteins, a balanced
daily diet should cover the daily requirements of
micronutrients, vitamins, and minerals. In chronic
disease, various causes increase the daily needs and
those patients, including COPD, frequently present
specific malnutritions, or deficiencies. The literature
about these issues is generally scarce, with some
recent exceptions presented but not limited to this
review. Research about vitamin D has moved our
interest beyond calcium and bone homeostasis to
enter the field of pulmonary function with inflam-
mation as a linking element [41]. The findings from
randomized trials were eagerly expected yet the bar
was apparently set too high. According to trial by
Lehouck et al. [42
&
], 100 000 IU of vitamin D supple-
mentation every 4 weeks for 1 year in 182 patients
with moderate to very severe COPD and a history of
recent exacerbations generally had no effect vs.
placebo on time-to-first exacerbation. Careful sub-
group analysis indicates potential benefit in patients
with severe vitamin D deficiency [rate of exacer-
bation ratio 0.57, 95% confidence interval (CI)
0.33–0.98]. Critically ill patients in need of mech-
anical ventilation have reduced serum levels of trace
elements (selenium, manganese, zinc) and supple-
mentation has the potential to shorten time spent
with mechanical ventilation support [43]. Some
confirmatory data for exacerbated COPD due to
upper respiratory tract infection were published
Translational research in wasting diseases
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recently. In a randomized, double-blind, placebo-
controlled trial, supplementation with Echinacea
purpurea along with zinc, selenium, and ascorbic
acid for 14 days but not with Echinacea purpurea
alone or with placebo resulted in significantly less
severe and shorter exacerbation episode [44]. Impor-
tantly, intervention was safe and well tolerated
with sleeping disorders occurring as most frequent
adverse events. The field of micronutrient supple-
ments appears promising with significant potential
for interventional trials.
GOING THE RIGHT DIRECTION: ANABOLIC
AGENTS AND PHYSICAL EXERCISE
Complementary to nutritional support are anabolic
interventions, which are already implemented for
patients with chronic respiratory failure [45].
Indeed, nutrients when only delivered as diet can
follow different metabolic pathways according to
current bodily needs. Anabolic steroids specifically
induce fat free mass gain, improve exercise capacity
and can restore response to rehabilitation program,
blunted by the low-dose oral steroids as mainten-
ance therapy [46]. Recent experimental evidence for
synergistic effects of anabolic steroids and glucocor-
ticoids on muscle recovery may be particularly
relevant in the recovery phase from an acute exacer-
bation [47].
Several other modalities or nutrients have
shown promising results in nonacute conditions.
Amino acids as main protein components are a
physiologically plausible target [48]. In COPD, the
splanchnic protein extraction is reduced when com-
pared to healthy age-matched controls. With milk
protein (high branched-chain amino-acid content)
supplementation, an enhanced anabolic response
was observed [49
&
] which could be relevant in acute
situations when protein needs are increased. Sub-
stituting whey with casein proteins further enhan-
ces the effects in terms of protein anabolism, both in
postprandial and exercise states [50
&&
].
The most potent physiological anabolic trigger is
physical training, in particular, resistance exercise.
During exacerbation, patients experience severely
limited physical performance, mainly due to dysp-
noea or infection. Thus, patients need to maintain a
sufficient anabolic drive through adjunctive inter-
vention, and data supporting feasibility and safety of
rehabilitation during or immediately after hospital-
ization are emerging. In a randomized trial compar-
ing low, moderate/high and no exercise during acute
exacerbation of COPD, adherence of 80% was
demonstrated and exercise was considered safe and
feasible [51]. One step further Babu et al. [52] random-
ized 38 patients during acute exacerbation of COPD
to regular physical therapy vs. regular and on-call
physical therapy. The addition of on-call sessions
increased 6-min walk distance and improved peak
expiratory flow. Feasibility, safety, and effects of
resistance training were investigated in a randomized
trial of 40 patients hospitalized for COPD exacer-
bation [53]. In addition to routine physiotherapy,
the intervention group performed three sets of eight
repetitions of quadriceps resistance exercise that
improved muscle strength and 6-min walk distance
at discharge and promoted more anabolic status in
skeletal muscle as investigated in biopsy samples. If
the patients are too ill to follow the physiotherapy or
if this is beyond available resources, transcutaneous
electrical muscle stimulation can be considered.
Meglic et al. [54
&
] tested the feasibility of this method
in 19 patients hospitalized due to COPD exacerbation
and demonstrated good tolerability, feasibility, and
safety of an average of 15 sessions per patient. Such
an intervention improved quadriceps strength,
which correlated to stimulation intensity during 14
sessions, without any adverse events [55]. To date, no
study has investigated the molecular or histological
profile of such an intervention starting at admission
to hospital. The best information comes from
Abdellaoui et al. [56
&&
] whoperformed skeletal muscle
biopsies in 15 patients who were randomized to
electrical muscle stimulation (N¼9) or placebo on
average 12 days after hospital admission. On top of
longer 6-min walk distance, they were able to dem-
onstrate a significant increase in type I fibres pro-
portion in patients receiving electrostimulation.
ARRIVAL: HOSPITALIZATION, THE
WINDOW OF OPPORTUNITY FOR
TREATMENT
The consensus of the authors is that our understand-
ing of pathophysiological mechanisms and processes
during bouts of COPD exacerbations remains insuf-
ficient. We also believe that translation from other
chronic diseases (that frequently coexist), space
medicine, and top-level sport is suboptimal. From
physiological perspective, most attractive thera-
peutic targets would be defense mechanisms (e.g.
sympathetic nervous system, renin-angiotensin-
aldosterone system, inflammation) that are activated
when exposed to acute metabolic stress. Further-
more, it seems plausible to block these systems on
a long-term basis to prevent cumulating damage,
which makes subclinical changes clinically import-
ant and mostly irreversible. In this context, physical
activity with all direct and indirect effects appears an
attractive target to focus on. Being the most effective
anabolic ‘remedy’, it has important effects beyond
physical performance. Through exercise, metabolic
COPD patient journey Lainscak et al.
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processes, acute defense mechanisms, and anabolic/
catabolic equilibrium are balanced to prevent the
body wasting and eventually cachexia. Finally, the
energy demands increase during deterioration thus
nutritional support is deemed as necessary to avoid
loss of the bodily reserves and tissues utilization.
CONCLUSION
Available evidence and ongoing research in the field
are scarce; we, however, anticipate this will change
shortly with the focus on both most feasible and
most sophisticated cutting edge interventions. First
step in patient assessment during exacerbation/hos-
pitalization should be comprehensive assessment
and identification of plausible intervention targets.
With evidence at hand, the stage is set for exercise or
muscle stimulation as a surrogate for normal daily
activity where there already is some guidance about
the timing and dose of the intervention. The nutri-
tional strategies to cover for specific needs during
exacerbation are less well investigated and simple
translation from stable chronic disease may not
be optimal. Transition of these strategies into the
chronic disease state should be the next step, with
particular emphasis on patient self-management.
Clinicians should not, however, be too much
focused on individual patients only and think more
globally. Many of the suggested interventions are
public health strategies to prevent and to control
chronic disease. With limited funding available, the
output and impact are therefore largely dependent
upon joint efforts and collaborative projects where
awareness about COPD, which appears poor among
lay public and patients [57], and all associated con-
sequences may be one of interim goals.
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